Market Signal Briefing

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

The Bitcoin market is often analyzed through price charts and macro trends, but a growing approach that focuses on something deeper is taking the spotlight. This approach is designed to track whether alignment between miners, investors, traders, and institutions is holding together or beginning to break down.

How Game Theory Applies To Bitcoin’s Market Structure The Bitcoin Game Theory framework offers a different lens on market structure, one that focuses on price and on participants that are acting in alignment or drifting apart. Its core purpose is to track coordination across the network and identify when that balance begins to break down.

According to a Delphi Digital post on X, in May 2022, the framework detected early signs of coordination fracturing and signaled a move to cash at $33,988. In the following months, BTC declined by an additional 54%. Meanwhile, a similar pattern emerged in October 2025, with the model exiting at $115,321, preceding a 45.5% drawdown.

In both instances, the regime classifier identified the shift in breakdown before the price confirmed the move. These downturns were characterized by speculative capital overwhelming patient capital, leading to a collapse in coordination. Delphi Digital stated that for allocators, the key question now is whether current market conditions justify continued structural exposure.

Source: Chart from Delphi Digital on X The current phase of the Bitcoin market reflects a transition between different groups of large holders, often referred to as whales. An analyst known as CW on X noted that long-term or old whales completed their accumulation phase last October and have finished positioning themselves well ahead of a potential rally. In contrast, a newer wave of whales is still in the process of building positions. 

This ongoing accumulation may be one of the key reasons behind the delay of the start of the rally. What makes this cycle unique is the expected shift in leadership. Historically, BTC bull runs have been driven primarily by a single dominant group of whales. However, this cycle is expected to be led by both old and new whales.

While the current market conditions may appear slow and uneventful, this accumulation dynamic suggests that underlying pressure is building. If both groups converge on their positions, the resulting rally could be significantly stronger than in previous cycles.

Why Bitcoin Revisiting Old Prices Is Not Bearish Crypto analyst Stockmoney Lizards has pointed out that the current timeline is obsessed with Bitcoin being at the same price it was in 2021. The key observation is that BTC should see a continuous growth, higher bases, and explosive bull markets.

If this trend continues, projections suggest that BTC could reach around $200,000 in 2027 and 2030, with potential expansion toward $500,000 in 2033 and 2035.

BTC trading at $66,311 on the 1D chart | Source: BTCUSDT on Tradingview.com Featured image from Pixabay, chart from Tradingview.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

Sign Up for Our Newsletter! For updates and exclusive offers enter your email.

Godspower Owie is my name, and I work for the news platforms NewsBTC and Bitcoinist. I sometimes like to think of myself as an explorer since I enjoy exploring new places, learning new things, especially valuable ones, and meeting new people who have an impact on my life, no matter how small. I value my family, friends, career, and time. Really, those are most likely the most significant aspects of every person's existence. Not illusions, but dreams are what I pursue.

At the time of writing, TRON [TRX] was up 0.85% over the past week – One of the only crypto assets in the top 20 by market cap to register gains over the past week. The altcoin had rallied to a local high of $0.317 on Friday, 27 March. However, it soon erased these gains and was down 1.48% in 24 hours.

And yet, since the early February crash, TRON has shown some resilience on the price charts. It was up by 15.47% in just over 7 weeks, and seemed to be in a position to challenge the mid-January high of $0.32.

This might be a no-trade zone for TRX until the altcoin reveals what is in store next.

Range formation and the triggers for the next TRX move Source: TRX/USDT on TradingView The 1-day trend appeared to be bullish, with the MACD reflecting upward momentum. At the same time, it was almost at the four-month range’s high at $0.319. The range’s low was at $0.271, and the rally since the February crash began from these lows.

As things stand, despite the relative strength of TRX recently, its bullish run might be ending soon. The OBV did not make new highs in recent weeks to show buyer dominance. If it had, it would have pointed towards a potential breakout.

The lacklustre OBV might be a result of the generally mediocre trading volume in the TRON markets since December. No uptrend since then has been borne by extraordinary volume.

Should trader bias flip bearish or remain bullish? Source: TRX/USDT on TradingView The H4 timeframe’s structure has remained bullish, though momentum and the OBV have begun to recede too. The retest of $0.309 on Friday, 27 March, saw a positive reaction in recent hours.

And yet, the higher timeframe range must be respected until it is cleanly breached. Therefore, despite the short-term bullish structure, TRX traders and investors can look to take profits and prepare for a move towards the range lows.

Meanwhile, a daily session closing above $0.32 would invalidate the bearish bias outlined here.

Final Summary TRON has been steadily bullish since the market crash in the first week of February. The four-month range formation’s highs are being tested, but TRX might have finished its rally already. 

TLDR: Aave founder Stani Kulechov called Whop Treasury one of the biggest DeFi-to-fintech integrations ever built.
Whop Treasury converts user balances to USDT0 stablecoins, routing funds through Veda Labs vaults on Plasma Network.
Funds deposited into Aave lending markets earn autocompounded yield with no gas fees or manual management required.
Whop’s 21 million users now access transparent, verifiable onchain financial infrastructure directly through the platform. Whop Treasury has drawn attention from one of DeFi’s most recognized figures. Aave founder Stani Kulechov publicly praised the integration, calling it a landmark moment for decentralized finance entering mainstream fintech.

Whop, a marketplace where creators sell digital products and community access, now routes user balances through onchain infrastructure to generate yield automatically.

With 21 million users and over $1 billion in creator sales last year, the platform’s move carries considerable weight in both crypto and commerce circles.

Why Kulechov Views Whop Treasury as a Turning Point Stani Kulechov described Whop Treasury as “one of the biggest DeFi-to-fintech integrations ever.” His praise centers on how the system connects a large, active user base directly to onchain financial infrastructure.

Most fintechs still depend on traditional payment rails with high fees and multiple intermediaries. Whop chose a different path entirely.

According to Kulechov, stablecoins bypass credit card networks and banks, cutting cost margins for both the platform and its users.

Whop just pulled off one of the biggest DeFi-to-fintech integrations ever.

Whop is a marketplace where creators make money selling digital products, and it has been gaining serious traction. On Whop, creators can sell online courses, tools, digital downloads and community…

— Stani.eth (@StaniKulechov) March 28, 2026

That cost reduction is not just theoretical. It directly affects how competitive Whop can remain as it scales globally across digital commerce.

Kulechov also pointed to transparency as a core advantage. Unlike traditional financial systems with complex agreements and manual processes, onchain infrastructure is publicly verifiable. Users can confirm exactly where funds go and how yield is generated.

He further noted that Whop’s model serves as a blueprint for the broader fintech industry. In his view, more platforms will follow this path, but Whop broke ground first by showing how it can work at scale.

The Technical Stack Behind the Treasury Integration Whop Treasury works through a layered onchain system. When a user opts in, their balance converts to USDT0 stablecoins provided by Tether.

Those funds then move through a Veda Labs vault operating on the Plasma network, a blockchain purpose-built for stablecoin transactions.

From there, capital flows into Aave lending markets, where it earns yield automatically. The autocompounding feature continuously redeploys returns without requiring users to pay gas fees or manage any positions manually. Card and crypto deposits are processed through MoonPay, keeping the entry point accessible.

Each layer of the stack has a defined role. USDT0 handles stablecoin conversion, Plasma manages low-cost transfers, Veda directs capital allocation, and Aave generates the actual yield. Together, they form a system that runs without intermediaries or manual oversight.

Kulechov described this as a masterclass in building an institutional-grade earn stack. The combination removes black boxes from the equation and gives users access to programmable financial tools that are global from day one.

For a platform with Whop’s reach, that infrastructure shift is more than a product update. It is a signal of where digital commerce finance is heading.

Shiba Inu prints a death cross on its hourly chart as over $441 million in crypto positions are liquidated.

Shiba Inu printed a death cross on its hourly chart this week, a technical signal that emerged amid a broader crypto market sell-off. Over $441 million in trading positions were liquidated overnight, putting pressure across digital assets. The pattern formed as the 50-period moving average dropped below the 200-period moving average on the one-hour timeframe, a classic bearish signal that often precedes further short-term downside.

The sell-off followed the year's largest options expiry event for Bitcoin and Ethereum. Roughly $14 billion worth of Bitcoin options expired Friday, measured by open interest. Traders shifted to defensive positions ahead of and after the expiry, contributing to the broad market weakness. Investor outflows from crypto exchange-traded funds added further selling pressure, reinforcing the cautious mood across the sector.

SHIB Price Battles Key Resistance LevelsShiba Inu declined for three consecutive days beginning March 25. The drop was driven by profit-taking as investors weighed persistent macroeconomic headwinds. The death cross formed during this stretch of selling.

At the time of writing, SHIB traded at $0.00000577, down 2.18% over the past 24 hours. The token rebounded from a low of $0.00000571, suggesting buyers stepped in at that level. Whether that floor holds will be a key factor in determining SHIB's short-term direction.

The immediate challenge for SHIB is the one-hour 50 MA, which now acts as resistance. Price has stalled near this barrier during the current relief rally. A clean break and close above the 50 MA would open the path toward the one-hour 200 MA, currently sitting at $0.00000596. That level represents the next meaningful target for bulls attempting to reclaim momentum.

Until SHIB clears these resistance zones with sustained buying, the relief rally remains fragile. Traders are watching closely for confirmation that $0.00000571 has been established as solid support. A failure to hold that level could expose SHIB to fresh downside.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Newton Gitonga covers cryptocurrencies, blockchain, and digital finance. He specializes in breaking down complex trends with clear, data-driven reporting. His work focuses on market analysis, technical insights, and the evolving role of altcoins in shaping global markets.

Read more about

Latest Shiba Inu News Today (SHIB)

XRP Ledger has moved back into focus after on-chain activity rose above 120 transactions per second, with blocks carrying about 600 to 700 transactions. The increase came as Ripple also continued RLUSD supply adjustments, including fresh minting on XRPL and burns on Ethereum. At the same time, XRP traded near $1.35, leaving market participants focused on both network usage and price structure. 

Ripple News: XRPL Throughput Rises as DEX Cancellations Lift Transaction CountRecent network data shared by XRPL validator Vet showed XRP Ledger processing more than 120 transactions per second over a sustained period. The validator said blocks were handling roughly 600 to 700 transactions each, showing that the ledger was managing a dense flow of activity without abnormal fee pressure.

The reported surge did not come from payment transfers alone. Instead, much of the volume came from decentralized exchange activity, especially offer cancellations. That pattern suggested traders were adjusting or removing existing orders rather than entering a wave of new positions. The activity still showed that the network could process a heavy stream of instructions in real time.

Vet shared a short live view of XRPL transaction flow to show the pace and consistency of network processing. The display gave the community a direct look at how the ledger was handling the load. Community responses varied, but the validator kept the focus on network behavior and execution rather than price reaction.

He explained that cancellations simply reflected users removing earlier DEX offers. Therefore, the surge is an operational event inside the exchange layer of XRPL, not a sudden rise in capital transfers. Even so, the volume gave developers and users a fresh look at how the ledger performs under heavier traffic.

RLUSD Minting Adds Another Layer to XRPL ActivityAlongside the jump in ledger activity, Ripple’s stablecoin also recorded new supply movements. In the last 24 hours, 9 million RLUSD were minted on the XRP Ledger through two transactions, one for 4 million and another for 5 million tokens. During the same period, more than 10 million RLUSD was burned on Ethereum, pointing to another round of supply rebalancing across networks.

March has seen repeated RLUSD minting and burning activity as Ripple expands the token’s role in enterprise settlement and payments. A larger share of total RLUSD supply still sits on Ethereum, but the fresh minting on XRPL keeps attention on the ledger’s role in Ripple’s broader stablecoin strategy.

Ripple has also tied RLUSD growth to real-world payment use cases. The company recently began a pilot in Singapore’s MAS BLOOM sandbox to support cross-border trade payments using RLUSD and XRP Ledger infrastructure. That step adds context to the recent minting activity, as Ripple continues to position the stablecoin for business payment flows.

XRP Price Stays Under PressureWhile XRPL activity and RLUSD supply changes drew attention, XRP price remained below a level some analysts view as critical. XRP traded around $1.35 on March 28, leaving it roughly 30% below the $1.70 key resistance level with a 1.38% rally in the last 24 hours.

According to that view, a move above $1.70 could shift XRP from consolidation into a stronger upward trend. The same analysis pointed to April or May 2026 as a possible window for a larger rally if that level turns into support. XRP would still need a much larger gain to move beyond its previous all-time high of $3.84 from January 2018.

For now, XRP remains tied to broader market conditions as well as crypto-specific catalysts. That leaves traders watching whether rising ledger activity, RLUSD growth, and continued use of XRPL services can support stronger market interest

TLDR: HyperCore repurchased 34,495.71 HYPE at $38.51 on March 27, exceeding daily staking distributions. A net 7,711 HYPE were permanently removed from circulation, projecting to 2.77M tokens yearly. Unlike Solana’s 25.19M annual inflation, Hyperliquid is actively reducing its total token supply. Higher HIP-3 adoption drives more revenue, fueling larger buybacks and compounding deflation pressure. Hyperliquid recorded net deflation on March 27, 2026, as HyperCore repurchased more HYPE tokens than it distributed.

The buyback totaled 34,495.71 HYPE at an average price of $38.51. Against 26,784 HYPE paid out to stakers and validators, the net removal stood at 7,711 tokens.

This marks a notable shift in how the protocol manages its circulating supply.

Buyback Activity Drives Daily Supply Reduction On March 27, HyperCore’s repurchase program pulled 34,495.71 HYPE from circulation. The distribution of 26,784 HYPE went to stakers and 24 active validators on the same day. After accounting for both figures, 7,711 HYPE were permanently removed from supply.

At this pace, the monthly net reduction reaches approximately 231,330 HYPE. Annually, that projects to nearly 2,775,960 HYPE taken out of circulation. These numbers reflect a consistent deflationary trend rather than a one-time event.

According to Hyperliquid Hub, the buyback mechanism also responds to price movement. When HYPE trades higher, fewer tokens are repurchased per dollar spent. When prices fall, the protocol buys back more aggressively, which naturally manages supply pressure.

Deflation

On March 27, 2026, HyperCore repurchased 34,495.71 HYPE at an average price of approximately $38.51

On the same day:

26,784 HYPE were distributed as rewards to stakers and 24 validators

Net Effect
34,495.71− 26,784 = 7,711 HYPE
➡️ Net tokens permanently removed… https://t.co/IzWha43Ces pic.twitter.com/DeqhHMA6Md

— Hyperliquid Hub (@Hyperliquid_Hub) March 28, 2026

Protocol Revenue Feeds a Self-Reinforcing Cycle The deflation model ties directly to trading activity on the network. More adoption of HIP-3 leads to higher trading volumes across the platform. That activity generates greater protocol revenue, which then funds larger buyback operations.

As Hyperliquid Hub noted, this creates a flywheel: “More HIP-3 adoption → higher trading activity → more protocol revenue → larger buybacks.”

Each component reinforces the next without requiring external intervention. The system is built to scale its deflationary pressure alongside usage.

For context, Solana issues roughly 25.19 million SOL annually through its staking and validator reward structure. Hyperliquid, by contrast, is removing more tokens than it issues on a daily basis. The two networks represent opposite ends of the supply management spectrum.

The price-sensitive nature of the buyback adds another layer of stability to the model. It functions as a built-in counter to extreme market swings in either direction. Over time, this structure may reduce volatility tied to supply-side selling pressure.

Ripple’s XRP is drawing fresh market attention as investors weigh two potential catalysts: growing expectations for U.S. crypto legislation and Ripple’s push to harden the security of the XRP Ledger (XRPL) using AI-driven testing. While XRP has largely moved sideways around the mid-$1.30 range, the narrative around regulatory clarity and institutional readiness is beginning to overshadow short-term price action.

As of Saturday, March 28, 2026 UTC, XRP traded near $1.35, up about 1% over the past 24 hours. On a weekly basis, however, it remained lower after retreating from roughly $1.44, reflecting a broader risk-off tone in digital assets. Market commentators attributed the pullback less to XRP-specific factors and more to macro headwinds such as ETF outflows across major crypto products and ongoing geopolitical uncertainty.

The immediate focus is on the fate of the proposed ‘CLARITY Act,’ which market participants see as a potential turning point for how major tokens are classified and supervised in the U.S. According to reports circulating in the crypto press, CFTC Chair Rostin Behnam and Ripple executives have suggested the bill is approaching its final stage. Traders are increasingly positioning around the idea that passage—possibly by late May—could open the door to deeper ‘institutional demand,’ including clearer pathways for banks to use XRP-related infrastructure and for issuers to launch new regulated products tied to the asset.

The stakes are high because the alternative scenario is simpler: if legislative progress stalls, XRP would likely remain more tightly correlated with the broader crypto market’s swings, limiting the ability of idiosyncratic adoption narratives to drive sustained re-pricing. In that context, even minor signals from Washington can become a dominant driver of sentiment, particularly for tokens whose institutional pitch hinges on compliance and integration with existing financial rails.

On-chain indicators have been interpreted as broadly constructive. Analysts tracking exchange balances have pointed to declining XRP holdings on centralized venues alongside increased accumulation by large holders—often viewed as a sign that market participants are building positions ahead of a possible regulatory catalyst. While such metrics can shift quickly, the combination of reduced sell-side liquidity and whale accumulation tends to be read as supportive for near-term price stability.

Ripple is also attempting to strengthen XRPL’s case as ‘institution-grade’ infrastructure. The company said it has overhauled security processes using AI-based red-team testing, identifying more than 10 vulnerabilities that were not detected through prior methods. A forthcoming update is expected to focus narrowly on bug fixes, an approach typically favored by enterprises that prioritize reliability and auditability over feature releases.

The push comes as Ripple and its partners highlight the network’s operational history. XRPL has processed more than 3 billion transactions across over 100 million ledgers, according to figures cited in recent coverage. Ripple CEO Brad Garlinghouse has repeatedly argued that XRP’s low fees and fast settlement are well-suited for modernizing payments—particularly cross-border flows where legacy systems remain costly and slow.

Adoption narratives continue to evolve. Recent reports have referenced real-world initiatives such as recording Dubai land registry activity on XRPL and ongoing collaboration involving Guggenheim, framing these as proof points that blockchain-based settlement is moving from experimentation toward production use. Garlinghouse has also characterized stablecoins as a “ChatGPT moment” for cross-border payments—an analogy intended to capture the speed at which a practical application can mainstream a technology once usability and distribution align.

Institutional positioning is also being closely watched. Multiple outlets have circulated claims that Goldman Sachs ($GS) holds approximately $152 million in XRP ETF exposure, and that the Monetary Authority of Singapore’s (MAS) BLOOM pilot is set to run for the third time within a month. While market participants generally treat such datapoints cautiously without corroborating disclosures, the broader trend is clear: investors are scanning for signs that regulated financial institutions are becoming more comfortable engaging with XRP-linked instruments and settlement pilots.

Garlinghouse has publicly suggested that 2026 could be a record year for Ripple, citing a mix of potential M&A activity and improving regulatory conditions as key tailwinds. The company’s core pitch remains that it can function as a bridge between ‘TradFi’ and ‘DeFi’ in a way that is resilient to day-to-day crypto volatility—an argument that resonates most when compliance uncertainty is reduced.

Not all commentary has been restrained. Some analysts have floated highly speculative targets—one claim suggested XRP could exceed $1,000 by the end of 2026 based on dark-pool activity and supply dynamics. Such projections remain unverified and far outside conventional valuation frameworks, prompting market observers to warn that they should not be treated as anything more than conjecture.

In the near term, the market appears less focused on incremental price moves and more on whether regulatory uncertainty will finally clear. If U.S. legislation advances and Ripple’s security hardening convinces risk committees, XRP could benefit from a renewed emphasis on ‘utility’ and regulated adoption. If not, XRP may continue to trade as a high-liquidity proxy for broader crypto sentiment—rising and falling largely with the market tide.

Article Summary by TokenPost.ai

🔎 Market Interpretation

- XRP is trading mostly sideways near $1.35, with near-term price action taking a back seat to two narratives: (1) possible U.S. regulatory clarity via the proposed “CLARITY Act,” and (2) Ripple’s efforts to make XRPL more institution-ready through AI-driven security testing.

- The recent pullback from ~$1.44 is framed as macro/market-wide (ETF outflows, geopolitical uncertainty) rather than XRP-specific weakness, implying XRP remains sensitive to broad risk sentiment until a token-specific catalyst lands.

- The market is increasingly “event-driven”: passage progress on U.S. legislation could re-rate XRP on compliance/utility expectations; stalling could keep XRP tightly correlated to overall crypto beta.

- On-chain signals cited (declining exchange balances + whale accumulation) are interpreted as supportive for near-term stability, suggesting reduced sell-side liquidity—though these indicators can reverse quickly.

- Institutional interest is discussed via unverified/uncorroborated reports (e.g., ETF exposure claims, MAS pilot timing). The takeaway is not the exact numbers, but the direction: investors are watching for regulated finance participation and settlement pilots as validation.

💡 Strategic Points

- Primary catalyst to monitor: U.S. “CLARITY Act” timeline and credible legislative milestones (committee movement, floor scheduling, finalized language). Market expectations cluster around a potential late-May window; any delays could quickly dampen narrative momentum.

- Secondary catalyst: Ripple’s “institution-grade” positioning of XRPL via AI-based red-team testing and a bug-fix–focused update. For enterprises, security posture and auditability can matter more than new features.

- Base-case trading implication: absent regulatory progress, XRP likely behaves as a liquid proxy for broad crypto risk-on/risk-off flows; with progress, idiosyncratic adoption and compliance narratives may drive relative outperformance.

- Risk management note: treat extreme price targets (e.g., “$1,000 by end of 2026”) as conjecture rather than forecast—especially when justified by opaque signals like “dark-pool activity” without verifiable data.

- Validation checklist for “institutional demand” claims:

1) Confirmed disclosures from regulated entities (filings, audited statements)

2) Clearly defined product structures (ETF/ETP prospectus language, custody details)

3) Evidence of production usage (transaction volumes tied to named programs)

4) Compliance pathways (licensing, supervisory guidance, classification outcomes)

📘 Glossary

- XRP: The native token associated with the XRP Ledger, often discussed as a liquidity/settlement asset.

- XRPL (XRP Ledger): The blockchain network that processes transactions and maintains ledgers; positioned for payments and settlement.

- CLARITY Act: Proposed U.S. crypto legislation referenced as potentially clarifying how major tokens are classified and supervised.

- CFTC: U.S. Commodity Futures Trading Commission; cited via its chair in relation to the bill’s perceived progress.

- Risk-off: Market environment where investors reduce exposure to higher-risk assets (often pressuring crypto prices).

- Exchange balances: Amount of a token held on centralized exchanges; declines are often interpreted as reduced near-term selling supply.

- Whale accumulation: Large-holder net buying/holding behavior; sometimes viewed as positioning ahead of catalysts.

- Red-team testing: Adversarial security testing that simulates attacks to discover vulnerabilities.

- Institutional-grade: Informal term implying reliability, security controls, and auditability suitable for regulated organizations.

- TradFi / DeFi: Traditional finance vs. decentralized finance; Ripple frames XRP as a bridge between the two.

- Stablecoins: Tokens typically pegged to fiat currencies; described here as accelerating mainstream utility in cross-border payments.

- ETF outflows: Net withdrawals from exchange-traded products; cited as a macro headwind impacting broader crypto sentiment.

Cardano has been stuck below 30 cents for weeks, and its ranking among global cryptocurrencies has slipped to 12th place. Against that backdrop, a trader is now arguing the coin could still reach $2 — and sooner than most people think.

The Math Behind The Claim The argument comes from Yesreel, a crypto trader with six years of experience, who posted the projection on social media.

Based on his analysis, ADA would only need to string together five to six days of 40–50% daily gains to close the gap between its current price and the $2 target. At roughly $0.25 right now, that gap works out to about 695%.

The calculation itself holds up. Compounding works fast when daily percentage gains are that large. A 40% jump per day for six straight days gets ADA to $2. A 50% daily gain does the same in five. The math is real. Whether those gains can happen is a different question.

$ADA can go to $2 faster than you think

It only needs a few consecutive days with 40%-50% pumps🚀

It has happened before, it can happen again.

— Yesreel (@Yesreel_) March 26, 2026

Yesreel says history gives reason to believe they can. Cardano hit an all-time high of $3.10 back in 2021, and it got there fast. Between August 2 and September 2 of that year, the token climbed from $1.32 to that peak — a gain of 134% in a single month.

More recently, following the US presidential election in November 2024, ADA surged over 160% in just 15 days, jumping from around 32 cents on November 5 to 84 cents by November 20.

Past Rallies Give Bulls Something To Point To Those two episodes are the backbone of the bullish case. Both showed that Cardano can move sharply and quickly when market conditions fall into place. Broad investor demand, a rising tide across the crypto market, and heavy capital inflows were the common thread in each case.

ADAUSD now trading at $0.24. Chart: TradingView The current picture looks different. Crypto markets have been weighed down by macroeconomic pressure and geopolitical tensions, and ADA has felt that drag more than most. The token has spent much of the past several weeks trading below 30 cents with little momentum to show for it.

Current Conditions Still Pose A Challenge No sustained breakout has materialized yet, and investor confidence in a near-term recovery remains shaky. Bearish pressure has been steady, and ADA’s slide to 12th in global crypto rankings reflects how much ground it has lost relative to other assets.

Yesreel has not offered a specific timeline or a trigger event that would kick off the kind of run he is describing. His projection rests on the idea that when the right conditions align — rising sentiment, strong inflows, momentum feeding on itself — ADA has shown it can compress months of gains into days. Whether those conditions arrive anytime soon is something no one can say with certainty.

Featured image from Unsplash, chart from TradingView

Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Shiba Inu Layer-2 blockchain Shibarium saw an unexpected drop in transactions, which fell from 10,940 to 1,230, representing an 88.3% decline in the last 24 hours.

On March 26, Shibarium saw a sudden comeback in transactions after remaining largely below 2,000 since February, surging as much as 300%, which was reported by U.Today.

However, this rise was not sustained as the transaction surge was quickly reversed, with Shibarium returning to its previous baseline, falling below 2,000.

HOT Stories

It was observed that recent transactions had the label "Value 0 BONE," being contract calls rather than direct wallet transfers. This same scenario also presented when Shibarium transactions rose on the previous day, sparking curiosity.

You Might Also Like

While the exact reason for the transaction drop remains unknown, sentiment dropped in the market, with most cryptocurrencies returning into losses as traders turned defensive.

The fact that the Shibarium blockchain, alongside its explorer, is undergoing an infrastructure upgrade also remains crucial to consider.

A total of 84% of blocks indexed on Shibarium explorerShibarium recently saw a major server migration while a full chain reindexing is ongoing and is not yet completed.

The Shibarium explorer sync is tending toward completion, with 84% of blocks now indexed. The Shibarium explorer is rebuilding from scratch, so the current data is partial only.

You Might Also Like

This does not, however, mean a slowdown for Shibarium as the indexing delay only affects its explorer, with the blockchain remaining intact.

The Shibarium network continues to run steady following its RPC migration; metrics on Shibariumscan remain below the real count, given an incomplete indexing.

The focus on Shibarium testnet Puppynet has shifted to Layer-3 with the Shib Alpha and ShibClaw development in progress. A new L3 explorer went live on March 21 for early testing.

At the time of writing, SHIB was up 0.85% in the last 24 hours to $0.000005813. Shibarium gas token Bone ShibaSwap (BONE) was up 1.22% in this time frame, trading at $0.06.

TLDR: Bitcoin has closed red for five straight months, from October 2024 through February 2025. A sixth red monthly close would tie the longest losing streak ever recorded in Bitcoin’s history.  Analyst van de Poppe identifies $60K as the ideal long entry if Bitcoin continues sweeping lower A clear break above $71K is the key level analysts say could fully reverse Bitcoin’s bearish trend.  Bitcoin is facing one of its most closely watched monthly closes in recent memory. The leading cryptocurrency has recorded red monthly closes for five straight months, from October through February.

March is on course to extend that run to six months. Currently trading at $66,000, the asset remains down on the month.

A sixth red monthly close would tie the longest streak in Bitcoin’s history. That record was last set between August 2018 and January 2019.

Bitcoin’s Longest Losing Streak on Record Within Reach The asset closed red in October, November, December, January, and February, marking five straight losing months. Trader Jeremy, known as @Jeremybtc on X, noted the historic nature of this run.

He pointed out that six consecutive red closes would match a record set between August 2018 and January 2019. March closes on Tuesday, with the price still sitting below its monthly open.

Bitcoin has closed red 5 months in a row.

October. November. December. January. February.

March closes on Tuesday.

Right now BTC is at $66k, down on the month.

Six consecutive red monthly closes would match the longest streak in Bitcoin's history.

The record was set… pic.twitter.com/0gU0erkEI6

— Jeremy (@Jeremybtc) March 27, 2026

That prior streak bottomed with Bitcoin near $3,400 at its lowest point. The asset then rallied roughly 300% over the following five months.

The 2018–2019 cycle remains one of the most referenced periods in the cryptocurrency’s short trading history. Many traders continue using it as a framework for reading current price behavior.

Bitcoin’s current level of $66,000 sits well above those earlier lows. The present correction, therefore, operates from a much higher base than the 2018 example.

Even so, the pattern of consecutive losing months draws clear comparisons between both periods. Traders are watching closely whether March confirms the sixth consecutive red monthly close.

The monthly close carries weight for both short-term traders and long-term holders. Any price movement before Tuesday could still shift the overall outcome.

For now, the current trajectory keeps a record-tying sixth red month firmly in view. Market sentiment has grown cautious as that deadline approaches.

Analysts Outline Key Price Levels to Watch Crypto analyst Michaël van de Poppe, known as @CryptoMichNL on X, shared his near-term outlook. He described the price action as following the same path seen during a prior consolidation phase.

He added that the asset would likely hold its range briefly before sweeping lower. Van de Poppe identified $60,000 as the ideal entry point for long positions if prices fall further.

#Bitcoin is not looking great.

The same procedure as during the previous consolidation. It will likely hang here for a bit, before continuing to sweep the lows further down the line.

If that happens, a sweep of $60K is the ideal area for longs on this one.

Now, what is going… pic.twitter.com/BvCVPmY648

— Michaël van de Poppe (@CryptoMichNL) March 28, 2026

The analyst also outlined what could shift his cautious view toward the upside. He stated that a clear break above $71,000 would change the overall perspective on Bitcoin.

Without that breakout level being reached, further downside remains his base case. His stance reflects a measured approach to reading the present market structure.

Van de Poppe further disclosed his personal trading plan heading into April. He said he would dollar-cost average into his altcoin portfolio on April 1st.

Lower prices, in his words, would actually work in favor of that strategy. This method is widely used among experienced traders who treat market dips as accumulation opportunities.

Taken together, both viewpoints place the market at a clear inflection point this week. Lower prices could draw fresh buyers in, while a push higher may restart an upward trend.

Traders remain divided on which outcome emerges next. The Tuesday monthly close may provide the most telling directional signal yet.

Investing in dividend stocks can be a good strategy for people who want to earn income from their stock portfolio. The best high-yield dividend stocks can also deliver strong growth. Though there are no guarantees in investing, some exchange-traded funds (ETFs) investing in dividend stocks, like the ProShares S&P 500 Dividend Aristocrats ETF (NOBL 0.60%), could even make you a millionaire -- if you're a patient, long-term investor. (The term Dividend Aristocrats® is a registered trademark of Standard & Poor's Financial Services LLC.)

This dividend ETF lets you invest in the S&P 500 Dividend Aristocrats®, a select group of companies that have grown their dividends for more than 25 years. As of December 2025, the fund paid a dividend yield of 2.55%.

Let's see how $10,000 in NOBL could become a million-dollar investment.  

Image source: Getty Images.

12 years of 11% average annual returns The ProShares S&P 500 Dividend Aristocrats ETF invests in a portfolio of 69 stocks and charges an expense ratio of 0.35%. Since the fund was established in October 2013, it's delivered average annual returns (by net asset value) of 11.1%. That's slightly better than the long-term average stock market return of 10% per year.

Today's Change

(

-0.60

%) $

-0.63

Current Price

$

104.57

But in the past year, NOBL has underperformed the S&P 500 index, gaining only 2.8% while the S&P 500 has gained about 15%. This fund has also underperformed the S&P 500 since its inception. Since October 2013, the S&P 500 is up about 292%, while this ETF has gained about 156%.

NOBL data by YCharts

So, why invest in this fund if it can't beat the S&P 500? You might consider this fund if you want to own stocks that typically deliver stable earnings and have strong track records of paying dividends. A dividend ETF like NOBL might also be less volatile than the rest of the S&P 500.

The NOBL fund's sector weighting is broadly tilted toward consumer staples (23.8% of the fund), industrials (21.2%), financials (12.2%), materials (11.4%), and healthcare (10.1%). Top holdings include energy stocks Chevron (1.8% of the fund), ExxonMobil (1.8%), and NextEra Energy (NEE +0.31%) (1.7%); as well as chemical company Linde (LIN 0.88%) (1.7%).

How $10,000 in NOBL could make you a millionaire Even if this dividend-stock fund doesn't outperform the S&P 500, it could still make you a millionaire. Turning $10,000 into $1 million would require a 9,900% jump.

Let's assume that NOBL keeps delivering its average annual return of 11.1%. At that rate of growth -- which is not guaranteed -- if you invest $10,000 in NOBL today, after 20 years, your money would grow to about $82,000. After 25 years, you'd have about $139,000. And after 44 years, your $10,000 NOBL investment would have reached over $1 million in this hypothetical example. 

Does that feel like too long to wait? Another approach would be to start by investing $10,000 in NOBL and then keep investing $500 per month. With average annual returns of 11.1%, you'd reach the million-dollar mark after 27 years. While future performance is not guaranteed and it would not be wise to put all your investing eggs into one security, owning top dividend stocks can be very rewarding. The ProShares S&P 500 Dividend Aristocrats® ETF is worth considering for long-term investors.

Ben Gran has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chevron, NextEra Energy, and ProShares S&P 500 Dividend Aristocrats ETF. The Motley Fool recommends Linde. The Motley Fool has a disclosure policy.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Franklin BSP Realty Trust, Inc. (NYSE: FBRT) between November 5, 2024 and February 11, 2026, both dates inclusive (the "Class Period"), of the important April 27, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

So what: If you purchased Franklin BSP Realty securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Franklin BSP Realty class action, go to https://rosenlegal.com/submit-form/?case_id=53434 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the Case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendants recklessly overstated Franklin BSP Realty's prospects; (2) defendants recklessly overstated Franklin BSP Realty's ability to maintain the $0.355 dividend; and (3) as a result, defendants' statements about Franklin BSP Realty's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Franklin BSP Realty class action, go to https://rosenlegal.com/submit-form/?case_id=53434 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY  10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of ODDITY Tech Ltd. (NASDAQ: ODD) between February 26, 2025 and February 24, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026.

SO WHAT: If you purchased Oddity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 11, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) due to an algorithm change by Oddity's largest advertising partner, Oddity's advertisements were being diverted to lower quality auctions at abnormally high costs; (2) the foregoing significantly increased Oddity's customer acquisition costs, thereby negatively impacting Oddity's business and financial prospects; (3) accordingly, defendants overstated the overall strength, stability, and sustainability of Oddity's digital operating model and/or market position; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Oddity class action, go to https://rosenlegal.com/submit-form/?case_id=27381 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290261

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of DNOW Inc. (NYSE: DNOW) resulting from allegations that DNOW Inc. may have issued materially misleading business information to the investing public.

So What: If you purchased DNOW Inc. securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=53946 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On February 20, 2026, StockStory published an article entitled “Why DNOW (DNOW) Shares Are Getting Obliterated Today.” The article stated that DNOW shares fell “after the company reported disappointing fourth-quarter 2025 financial results, which included a significant loss and missed Wall Street’s expectations.”

On this news, DNOW’s stock fell 19.1% on February 20, 2026.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lufax Holding Ltd (NYSE: LU) between April 7, 2023 and January 26, 2025, both dates inclusive (the "Class Period"), of the important May 20, 2026 in the securities class action first filed by the Firm.

So What: If you purchased Lufax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Lufax class action, go to https://rosenlegal.com/submit-form/?case_id=53703 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Lufax lacked adequate internal controls; (2) certain of Lufax's financial results were materially misstated; and (3) as a result, defendants' statements about Lufax's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lufax class action, go to  https://rosenlegal.com/submit-form/?case_id=53703 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY  10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Nektar class action, go to https://rosenlegal.com/submit-form/?case_id=55599 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) enrollment in the REZOLVE-AA trial had not followed applicable instructions and protocol standards; (2) the foregoing was likely to have a significant negative impact on the REZOLVE-AA trial's results; (3) accordingly, the REZOLVE-AA trial's overall integrity and prospects were overstated; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Nektar class action, go to https://rosenlegal.com/submit-form/?case_id=55599 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290258

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Late last year, AST SpaceMobile (ASTS 10.46%) launched Bluebird 6, the largest communications-array antenna ever in low Earth orbit (LEO), but the stock actually began soaring into the stratosphere earlier in 2025.

AST SpaceMobile's shares are up more than 196% over the past year and more than 11% so far in 2026. The buzz propelling that gain stemmed from the company's LEO satellites, which will enable 4G and 5G smartphones to connect from anywhere in the world, not just where ground-based cell towers and broadband are available. 

The company's latest satellite will deliver speeds of up to 120 megabits per second, enabling cellphones to do everything they do now with a direct connection -- streaming, talking, texting, etc. AST plans to launch 45 to 60 satellites by the end of this year. The bull case is obvious: AST will enjoy a significant first-to-market advantage in direct-to-device technology. It already has partnerships in place with AT&T, Verizon, Vodafone, Rakuten, Alphabet, American Tower, Nokia, and Saudi Arabian cellphone company stc Group. However, before you jump in and invest, you need to understand both AST SpaceMobile's challenges and its biggest advantage.

Image source: Getty Images.

Today's Change

(

-10.46

%) $

-9.19

Current Price

$

78.67

Ups and downs First, it's important to note that the stock's recent arc has been carrying it back down to Earth. 

AST SpaceMobile hit a 52-week high of $129.30 on Jan. 30, but by midday Friday, it was trading around $81, a pullback of about 37%. Much of that slide was likely due to the company's capital restructuring in mid-February. 

On Feb. 12, the company announced a private offering of $1 billion in senior convertible notes, due in 2036, and it also priced registered direct offerings of Class A common stock to fund the repurchase of older convertible notes. The company raised a total of $3.9 billion, but also increased its share count. The combination devalued the company's shares and raised concerns about the growing costs it faces as it ramps up its pace of satellite launches.

It's nowhere close to being profitable Launching satellites is expensive, and AST SpaceMobile needs to raise a lot more capital to fund its ambitious plans. In 2025, it took a big leap forward on the business front, reporting $70.9 million in revenue, up from $4.4 million in 2024. Even with that, it is still deeply unprofitable, booking a net loss of more than $340 million (or $1.34 per share) in 2025. As of the end of 2025, its long-term net debt had soared to $2.2 billion, and it had $2.3 billion in cash on the books, so even in the wake of its recent financial maneuvers, it will likely have to raise more to fund its efforts at some point.

That means it will likely sell more stock or raise money through its strategic partnerships. Either way, it will probably be years before it will have the potential to become consistently profitable.

Much of its eventual hoped-for value is already baked into the stock's price. Its price-to-sales ratio is a lofty 288.6, which means investors buying the stock today are paying more than $288 for every $1 in sales the company generates. So the market is obviously pricing the stock speculatively, based on an idea of what the company's earnings could potentially be.

The space race is definitely on Though AST SpaceMobile may have a bit of a lead in terms of deploying its satellite constellation at this point, other companies are jockeying to deliver similar services. SpaceX subsidiary Starlink already is providing basic direct-to-cell messaging, and unlike AST SpaceMobile, SpaceX has its own rockets. Lynk Global, a direct-to-device competitor, has a small fleet of satellites in orbit and is exploring bypassing ground-station bottlenecks by using a series of inter-satellite links.

Even AST SpaceMobile's cellular network partners could be competitors, in a sense. As 5G and future 6G coverage expands on the ground, the amount of land area not covered by terrestrial cell networks will likely shrink further, reducing the area where a satellite-based service like AST's would be a necessity.

However, the company does have a backer in the U.S. government. On Feb. 23, AST SpaceMobile announced it had landed a $30 million contract from the Space Development Agency. The agreement, executed under the Hybrid Acquisition for Proliferated Low-Earth Orbit program, shows that the technology has "dual-use" potential for secure tactical military communications, opening up a lucrative second revenue stream for it.

AST SpaceMobile stock has experienced pullbacks before, and so far, it has always come back higher. Now that the company is finally growing its revenues, the current pullback is offering investors another opportunity to get into what is certainly a growth stock, albeit one that faces some short-term risks.

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lufax Holding Ltd (NYSE: LU) between April 7, 2023 and January 26, 2025, both dates inclusive (the "Class Period"), of the important May 20, 2026 in the securities class action first filed by the Firm.

SO WHAT: If you purchased Lufax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lufax class action, go to https://rosenlegal.com/submit-form/?case_id=53703 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 20, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Lufax lacked adequate internal controls; (2) certain of Lufax's financial results were materially misstated; and (3) as a result, defendants' statements about Lufax's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lufax class action, go to https://rosenlegal.com/submit-form/?case_id=53703 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290268

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension at the 2026 American College of Cardiology.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care.

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR75 and up to 32% of patients achieving HiSCR100 An analysis of different hallmark lesions of HS shows that up to 25% of patients achieved inflammatory remission at Week 40, defined as a 100% reduction in abscesses (A100), nodules (N100) and draining tunnels (DT100)Patients treated with SLK also showed substantial improvements in HiSQOL items at week 40 versus baseline, ranging from 41% (pain), to 54% (walking, getting dressed) to 62% (down or depressed)Up to 43% of patients achieved an at least 3-point improvement from baseline in the worst skin pain NRS, while 65% of patients achieved an improvement of at least 4 points from baseline in DLQINo new safety signals were detected in the VELA trials to-dateDetailed results will be presented at the S034 Late-Breaking Research: Session 2 by Prof. Alexa Kimball, Investigator at Beth Israel Deaconess Medical Center, and Professor of Dermatology at Harvard Medical School, at the 2026 AAD Annual Meeting on March 28, 2026 ZUG, Switzerland, March 28, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces long-term Week 40 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with moderate-to-severe HS and confirms the presentation of the data at the 2026 American Academy of Dermatology (AAD) Annual Meeting later today.

The Phase 3 VELA program in adults with moderate-to-severe HS used the higher clinical response level of HS Clinical Response (HiSCR) 75 as the primary endpoint, which defines a response as an at least 75% reduction in abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count. Key secondary endpoints included the change from baseline in the HS Quality of Life score (HiSQOL) as well as other scores that reflect the evolving needs of HS patients, treating physicians and regulators. These included the percentage of participants achieving at least a 55% reduction in the International HS Severity Scoring System (IHS4-55), the percentage of participants achieving at least a 3-point improvement from baseline in the worst skin pain Numerical Rating Scale (NRS) among participants with a baseline score of at least 3 points, and the percentage of patients achieving a Dermatology Quality of Life Index (DLQI) total score improvement of ≥4 (minimal clinically important difference), among participants with a baseline DLQI ≥4. A total of 838 patients were enrolled across both trials. Following the primary endpoint at Week 16, patients in the placebo arm were switched to receive SLK treatment for the remaining duration of the trial until Week 52. Patients originally randomized to the SLK arm continued to receive SLK at the monthly 120mg maintenance dose. All patients have completed Week 40 and discontinuation rates were at the low end to those observed in other pivotal HS trials. After Week 52, patients have the opportunity to switch into a two-year open-label extension trial.

SLK demonstrated continued improvement of clinical scores and Patient Reported Outcomes (PROs) at Week 40. Across both VELA-1 and VELA-2, 62% of patients treated with SLK achieved HiSCR75 response and up to 32% of patients achieved HiSCR100 response at Week 40 (as observed). The results were consistent across both trials (VELA-1: 61.9% HiSCR75, 32.4% HiSCR100; VELA-2: 61.8% HiSCR75, 28.1% HiSCR100; as observed). Up to 77% of patients achieved an IHS-4 55 response (VELA-1: 74.3%, VELA-2: 77.4%; as observed) and up to 25% of patients achieved inflammatory remission at Week 40 (A100 + DT100 + N100; VELA-1: 25.2%, VELA-2: 21.1%; as observed).

With 62% of SLK patients reaching a HiSCR75 response already at Week 40, SLK sets a new standard in long-term lesion control of HS. Approved IL-17A and IL17A & F inhibitors reported HiSCR75 response rates of approximately 40% and 60%, respectively, at the 1-year mark of their respective pivotal trials (approved doses, pooled analysis across pivotal trials).

The strong long-term clinical responses were accompanied by continued improvement in PROs, which reflect critical quality of life outcomes for patients with HS. Patients treated with SLK showed a significant improvement of HiSQOL score at Week 40 with a -11.8 change from baseline in VELA-1, and -12.4 change from baseline in VELA-2 (mean HiSQOL at baseline of 26.5 (VELA-1) and 28.0 (VELA-2); as observed). While 59% of patients were within the “very severe” category on the HiSQOL severity score at baseline, 63% of patients were in the “mild / none” category at Week 40 (as observed, pooled). Improvements versus baseline in HiSQOL-Mini items ranged from 41% (pain), to 54% (walking, getting dressed) to 62% (down or depressed) at Week 40 (in patients with baseline >0, as observed, pooled). In addition, up to 43% of patients experienced a marked reduction of pain, as measured by an at least 3-point improvement from baseline in the worst skin pain NRS (VELA-1: 43.2%, VELA-2: 37.2%; as observed, baseline score of at least three points). 65% of patients achieved a meaningful (at least four points from baseline) improvement in DLQI (VELA-1: 64.6%, VELA-2: 65.3%; as observed, baseline DLQI of at least four points).

The safety profile of SLK in the VELA clinical trials remains consistent over time, with no new safety signals detected.

Prof. Alexa Kimball, President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Professor of Dermatology at Harvard Medical School said: “The Week 40 results from the VELA trials show an early and increasing clinical benefit over time for patients treated with sonelokimab, addressing a critical goal in HS treatment: long-term disease control. The consistency of the VELA data over time reinforces the opportunity for sonelokimab to address this important unmet need for patients living with HS.”

Details of the Week 40 results from Phase 3 VELA clinical trials in HS will be presented by Prof. Alexa Kimball at the 2026 AAD Annual Meeting (S034 Late-Breaking Research: Session 2). The presentation titled Sonelokimab in Moderate-to-Severe HS: Long-term Results through Week 40 of Two Phase 3 Trials will be on March 28, 2026 at 4pm – 4.12pm ET (2pm – 2.12pm MT).

Important upcoming anticipated milestones for MoonLake:  

Q2 2026: 52-week data of the VELA-1 and VELA-2 trials in HSMid 2026: Primary endpoint readout of the Phase 3 IZAR-1 trial in PsAH2 2026: Submission of a BLA for HSH2 2026: Primary endpoint readout of the Phase 3 IZAR-2 trial in PsA -Ends-

MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody® for the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The Company’s focus is on inflammatory diseases with a major unmet need, including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis and palmoplantar pustulosis – conditions affecting millions of people worldwide with a large need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available at www.moonlaketx.com.

About Nanobodies®
Nanobodies® represent a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable regions of heavy-chain-only antibodies (VHH). Nanobodies® have a number of potential advantages over traditional antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and their ability to be designed into multivalent therapeutic molecules with bespoke target combinations.

The terms Nanobody® and Nanobodies® are trademarks of Ablynx, a Sanofi company.

About Sonelokimab
Sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody® consisting of three VHHs covalently linked by flexible glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab at sites of inflammatory edema.

Sonelokimab is being assessed in two lead indications, hidradenitis suppurativa (HS) and psoriatic arthritis (PsA), and the Company is pursuing other indications in dermatology and rheumatology, including adolescent HS, palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA).

For adults with HS, sonelokimab is being assessed in two identical Phase 3 trials, the VELA-1 and VELA-2 trials, using the higher clinical response level of HS Clinical Response (HiSCR) 75 as the primary endpoint, which defines a response as an at least 75% reduction in abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count. In September 2025, the primary endpoint data from the VELA-1 and VELA-2 clinical trials were announced. In the combined VELA program, patients treated with SLK experienced a clinically meaningful and statistically significant improvement across all primary and key secondary endpoints using both pre-specified strategies (p<0.001). In VELA-1, SLK achieved statistical significance for all primary and key secondary endpoints using both pre-specified strategies (HiSCR75, delta to placebo of 17%, p<0.001). In VELA-2, intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy (HiSCR75, delta to placebo of 9%, p=0.053). From week 16, all patients are expected to continue to receive the 120mg dose of SLK through to 48 weeks, with a last assessment planned at week 52, followed by an open-label extension for up to two years. The safety profile of sonelokimab in the VELA trials was consistent with previous trials with no new safety signals detected.

Sonelokimab is currently undergoing evaluation in the VELA-TEEN Phase 3 trial, which is the first clinical study specifically focused on adolescent patients with moderate-to-severe HS.

For PsA, sonelokimab is being assessed in the Phase 3 trials, IZAR-1 and IZAR-2, following the announcement in March 2024 of the full dataset from the global Phase 2 ARGO trial (M1095-PSA-201) evaluating the efficacy and safety of the Nanobody® sonelokimab over 24 weeks in patients with active PsA. Significant improvements were observed across all key outcomes, including approximately 60% of patients treated with sonelokimab achieving an American College of Rheumatology (ACR) 50 response and Minimal Disease Activity (MDA) at week 24. This followed the positive top-line results in November 2023, where the trial met its primary endpoint with a statistically significant greater proportion of patients treated with either sonelokimab 60mg or 120mg (with induction) achieving an ACR50 response compared to those on placebo at week 12. All key secondary endpoints in the trial were met for the 60mg and 120mg doses with induction. The safety profile of sonelokimab in the ARGO trial was consistent with previous trials with no new safety signals detected.

Sonelokimab is also being assessed in PPP, a debilitating inflammatory skin condition affecting a significant number of patients, including in the completed Phase 2 LEDA program. In the Phase 2 LEDA clinical trial in PPP, SLK demonstrated clinically meaningful and statistically significant benefit. Patients treated with SLK achieved a mean percent change from baseline in the Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI) of 64% at week 16, and 39% of patients achieved a ≥75% reduction in the PPPASI (PPPASI75), suggesting that SLK could provide clinically meaningful improvements in this disease for which there are currently no approved therapies. The safety profile of SLK in the LEDA trial was consistent with previous trials with no new safety signals detected. 

Additionally, Sonelokimab is being assessed in the ongoing Phase 2 S-OLARIS and P-OLARIS trials for active axSpA and PsA, respectively. Both trials feature an innovative design complementing traditional clinical outcomes with cellular imaging techniques.

Sonelokimab has also been assessed in a randomized, placebo-controlled third-party Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe plaque-type psoriasis. High threshold clinical responses (Investigator’s Global Assessment Score 0 or 1, and Psoriasis Area and Severity Index 90/100) were observed in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab generally presented a safety profile similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575).

In an earlier third-party Phase 1 trial in patients with moderate-to-severe plaque-type psoriasis, sonelokimab decreased (to normal skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019; 81:196–203).

About the VELA program
The Phase 3 VELA program has enrolled over 800 patients across VELA-1 and VELA-2. Both global, randomized, double-blind, and placebo-controlled trials are identical in design evaluating the efficacy and safety of the Nanobody® sonelokimab, administered subcutaneously, in adult patients with active moderate-to-severe hidradenitis suppurativa. Similar to the design of the landmark Phase 2 MIRA trial, the primary endpoint is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75, defined as a ≥75% reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline. The trials also evaluate a number of secondary endpoints, including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4), the proportion of patients achieving a Dermatology Life Quality Index (DLQI) total reduction of ≥4, the proportion of patients achieving at least 50% reduction from baseline in Numerical Rating Scale (NRS50) in the Patient’s Global Assessment of Skin Pain (PGA Skin Pain) and complete resolution of Draining Tunnels (DT100). The VELA protocols and statistical analysis plans were prepared in accordance with regulatory agency advice and include two analysis strategies. The composite strategy for the VELA trials (also referred to as the primary estimand) is the primary statistical analysis. The protocol specifies the treatment policy strategy as the alternative method of handling intercurrent events to test the robustness of the VELA data. The trials compare a single 120mg dose of sonelokimab to placebo with HiSCR75 reading out at week 16. Results of the week 16 data were announced in September 2025. Further details are available under NCT06411899 and NCT06411379 at www.clinicaltrials.gov.

About the MIRA trial
The MIRA trial (M1095-HS-201) is a global, randomized, double-blind, placebo-controlled Phase 2 trial to evaluate the efficacy and safety of the Nanobody® sonelokimab, administered subcutaneously, in the treatment of adult patients with active moderate-to-severe hidradenitis suppurativa. The trial recruited 234 patients, with the aim to evaluate two different doses of sonelokimab (120mg and 240mg) with placebo control and adalimumab as an active reference arm. The primary endpoint of the trial is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75), defined as a ≥75% reduction in total abscess and inflammatory nodule (AN) count with no increase in abscess or draining tunnel count relative to baseline. The trial also evaluated a number of secondary endpoints, including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score System (IHS4), the proportion of patients achieving a Dermatology Life Quality Index (DLQI) total score of ≤5, and the proportion of patients achieving at least 30% reduction from baseline in Numerical Rating Scale (NRS30) in the Patient’s Global Assessment of Skin Pain (PGA Skin Pain). Further details are available under NCT05322473 at www.clinicaltrials.gov.

About the VELA-TEEN trial
The Phase 3 VELA-TEEN trial is an open-label, single-arm trial designed to evaluate sonelokimab 120mg administered subcutaneously once every two weeks (Q2W) until week six and once every four weeks (Q4W) from week eight onwards. The trial aims to enroll 30-35 adolescents, aged 12-17, with moderate-to-severe hidradenitis suppurativa, from U.S. sites experienced in clinical trials and pediatric dermatology. The primary trial phase will be 24 weeks with a primary endpoint evaluating the pharmacokinetics, safety, and tolerability of sonelokimab. VELA-TEEN will also evaluate several secondary endpoints, including the proportion of patients achieving the higher clinical response measure of the Hidradenitis Suppurativa Clinical Response Score (HiSCR) 75, in addition to HiSCR50. Other outcomes are the change from baseline in the International Hidradenitis Suppurativa Severity Score System (IHS4), which includes the quantitative measure of draining tunnels, and the proportion of patients achieving a meaningful reduction of the Children’s Dermatology Life Quality Index (CDLQI) and the Patients Global Assessment of Skin Pain (PGA Skin Pain). Further details are available under NCT06768671 at www.clinicaltrials.gov.

About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a severely debilitating chronic skin condition resulting in irreversible tissue destruction. HS manifests as painful inflammatory skin lesions, typically around the armpits, groin, and buttocks. Over time, uncontrolled and inadequately treated inflammation can result in irreversible tissue destruction and scarring. The disease affects an estimated 2% of the population, with three times more females affected than males. Real-world data in the United States indicates that at least 2 million unique patients have been diagnosed with and treated for HS between 2016 and 2023 alone, highlighting a significant unmet need and impact on healthcare systems, and a market opportunity projected to reach $15bn by 2035. Onset typically occurs in early adulthood and HS has a profound negative impact on quality of life, with a higher morbidity than other dermatologic conditions. There is increasing scientific evidence to support IL-17A- and IL-17F-mediated inflammation as a key driver of the pathogenesis of HS, with other identified risk factors including genetics, cigarette smoking, and obesity.

About the IZAR Program

IZAR-1 (NCT06641076) and IZAR-2 (NCT06641089) are global, randomized, double-blind, placebo-controlled Phase 3 trials designed to evaluate the efficacy and safety of sonelokimab compared with placebo in a total of approximately 1,500 adults with active psoriatic arthritis (PsA), with a primary endpoint of superiority to placebo in American College of Rheumatology (ACR) 50 response at Week 16. IZAR-1 is expected to enroll biologic-naïve patients and include an evaluation of radiographic progression, while IZAR-2 is expected to enroll patients with an inadequate response to tumor necrosis factor-α inhibitors (TNF-IR) — reflecting patients commonly seen in clinical practice — and is the first PsA trial to include a risankizumab active reference arm. Both trials will also assess a range of secondary endpoints reflecting the multiple disease manifestations characteristic of PsA. These include skin and nail outcomes, multidomain outcomes, and patient-reported outcome measures such as pain and quality of life assessments. Further details are available under NCT06641076 and NCT06641089 at www.clinicaltrials.gov.

About Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic, progressive and complex inflammatory disease that manifests across multiple domains, leading to substantial functional impairment and decreased quality of life. The clinical features of PsA are diverse, comprising both musculoskeletal (peripheral arthritis, spondylitis, dactylitis, and enthesitis) and non-musculoskeletal (skin and nail disease) domains. PsA occurs in up to 30% of patients with psoriasis, most commonly those aged between 30 and 60 years. Although the exact mechanism of disease is not fully understood, evidence suggests that activation of the IL-17 pathway plays an important role in the disease pathophysiology.

About the S-OLARIS trial
The S-OLARIS trial (M1095-axSpA-201) is a Phase 2 trial designed to evaluate the efficacy and safety of sonelokimab 60mg administered subcutaneously in adult patients with active axial spondyloarthritis (axSpA). The trial recruited 26 patients. The primary endpoint is the change from baseline (CfB) in 18F-NaF SUVmax signals at week 12 in the sacroiliac joints and spine as detected by PET. Throughout the trial, several other endpoints will be assessed including established clinical disease activity outcomes (e.g., ASAS), scores related to physical function, spinal mobility, and enthesitis as well as patient reported outcomes. The trial also features an innovative exploratory peripheral blood and tissue biomarker program.

The trial design has been informed by previous successful studies of sonelokimab, including the landmark Phase 2 ARGO trial in psoriatic arthritis, which identified the optimal dosing and demonstrated the potential of sonelokimab to target deep tissue inflammation effectively. Further details are available under EUCT number 2024-513498-36-00 at https://euclinicaltrials.eu.

About Axial Spondyloarthritis
Axial Spondyloarthritis (axSpA) typically impacts young people, with diagnosis based on chronic inflammatory back pain lasting more than three months with onset under 45 years of age. Advanced disease can lead to progressive and pathologic bone formation and joint fusion, severely limiting spinal mobility. Global reported prevalence of axSpA ranges from 0.5% to 1.5%. AxSpA can be categorized by disease progression into two subtypes: non-radiographic axSpA and ankylosing spondylitis (AS), also known as radiographic axSpA, which is diagnosed based on radiographic evidence of structural changes to the sacroiliac joints. Patients with axSpA experience fatigue, persistent morning stiffness, and pain that worsens at night and can disrupt sleep. Many patients also face the burden of comorbidities such as psoriatic arthritis and psoriasis. Studies have found elevated IL-17 levels in the blood and synovial fluid of patients with axSpA, and IL-17A and IL-17F are both thought to be key contributors to pathogenesis across the spondyloarthropathies.

About the LEDA Trial
The LEDA trial (M1095-PPP-201) is a Phase 2 trial designed to evaluate the efficacy and safety of sonelokimab 120mg administered subcutaneously in adult patients with palmoplantar pustulosis (PPP). The trial recruited 32 patients. The primary endpoint of the trial is percent change from baseline in Palmoplantar Psoriasis Area and Severity Index (ppPASI) with important secondary endpoints including ppPASI75 (at least 75% improvement in the ppPASI). The LEDA trial features an innovative translational research program using peripheral blood and tissue biomarkers as trial controls.

The trial design has been informed by previous successful studies of sonelokimab, including the landmark Phase 2 MIRA trial in hidradenitis suppurativa, which identified the optimal dosing and demonstrated the potential of sonelokimab to target deep tissue inflammation effectively. Further details are available under EUCT number 2024-513305-32-00 at https://euclinicaltrials.eu.

About Palmoplantar Pustulosis
Palmoplantar Pustulosis (PPP) is characterized by the development of blister-like pustules within erythematous, scaly plaques on the palms and the soles of the feet. PPP typically develops in adulthood, more frequently impacts females. Patients frequently experience significant pain, burning, and itching sensations on the palms and soles of the feet which can be debilitating and impair their ability to work, sleep, or perform other activities of daily living. Currently, the treatment of PPP is challenging with a significant unmet need for novel therapies to reduce the symptom burden for patients. Evidence suggests that activation of the IL-17 pathway has an important role in disease pathophysiology.

Cautionary Statement Regarding Forward Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the efficacy and safety of sonelokimab for the treatment of moderate-to-severe HS; potential market opportunities for sonelokimab; and upcoming anticipated clinical milestones, including data of the VELA-1 and VELA-2 trials in HS, the primary endpoint readouts of the Phase 3 IZAR-trial in PsA, Phase 3 VELA-TEEN trial in adolescent HS and Phase 3 IZAR-2 trial in PsA and submission of a BLA for HS. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

Forward-looking statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with MoonLake’s business in general and limited operating history; difficulty enrolling patients in clinical trials; state and federal healthcare reform measures that could result in reduced demand for MoonLake’s product candidates; reliance on third parties to conduct and support its preclinical studies and clinical trials; and the other risks described in or incorporated by reference into MoonLake’s Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings with the Securities and Exchange Commission.

Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any such statement is based.

Dr. Kimball is a paid consultant for MoonLake Immunotherapeutics.

Contacts:

MoonLake Immunotherapeutics Media & Investors Relations
[email protected]

ICR Healthcare
Mary-Jane Elliott, Sarah Elton-Farr, Ashley Tapp
Tel: +44 (0) 20 3709 5700
[email protected]

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost clear skinFollowing positive Phase 2 LILAC results, litifilimab is the only investigational program with consistent, positive efficacy results in multiple CLE studies; if approved litifilimab could be the first targeted therapy for this diseaseCLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement
CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). Litifilimab is the first humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2), which has the potential to become the first innovative therapy approved for CLE in 70 years. Part A of AMETHYST evaluated the efficacy and safety of litifilimab through week 24, with reductions in skin disease activity reported across several measures. Results are consistent with the earlier positive Phase 2 LILAC study reported in The New England Journal of Medicine. Phase 2 results from LILAC and AMETHYST supported litifilimab’s recently granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation. Results are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.

“We now have consistent results from two Phase 2 studies of litifilimab showing notable reductions in CLE skin disease activity, representing a significant moment for this program. I am encouraged by these results, which support the potential to bring litifilimab to patients with cutaneous lupus erythematosus, a condition where no targeted therapies are currently approved and where there are significant unmet needs,” said Joseph F. Merola, M.D., Professor and Chair, Department of Dermatology and Professor of Internal Medicine in the Division of Rheumatic Diseases, UT Southwestern Medical Center. “These findings, alongside the FDA Breakthrough Therapy Designation, underscore the potential, if approved, of litifilimab for patients living with this challenging disease. In addition to the efficacy results, litifilimab demonstrated a safety profile consistent with prior studies. Importantly, this trial intentionally enrolled a globally representative population reflective of the heterogeneity of CLE, including many participants with moderate to severe disease at baseline.”

CLE is a complex, heterogenous disease that affects millions of people around the world. Today there are no targeted therapies approved to treat CLE.

AMETHYST is an ongoing seamless two-part, multicenter, double-blind, placebo controlled, randomized study to evaluate the efficacy and safety of litifilimab compared to placebo in participants with a variety of CLE severities. Participants are randomized to receive subcutaneous treatment with litifilimab with standard of care (SoC) or placebo every four weeks in addition to SoC. All participants will receive litifilimab during the 28-week extended treatment period from Weeks 24 to 48. Results reported here are from the double-blind, placebo-controlled Phase 2 (Part A) portion of AMETHYST, Week 0 to 24. In the study, 74% of participants are women and 33% are non-white. This demographic distribution is consistent with the epidemiology of CLE which disproportionately affects women and diverse ethno-racial groups. The Phase 3 part of the study is ongoing and results remain blinded.  

AMETHYST Part A met its primary endpoint with litifilimab demonstrating a statistically significant 11.8% higher reduction in disease activity in people living with CLE (95% confidence interval [CI]: 1.39, 22.27; p < 0.05) as measured by the Cutaneous Lupus Activity Investigators’ Global Assessment Revised (CLA-IGA-R) erythema score of 0-1 (clear/almost clear) at Week 16, compared to placebo (14.7% vs. 2.9%). Secondary endpoints, including the following, were not adjusted for multiplicity in Part A and therefore statistical significance cannot be demonstrated. Litifilimab was associated with rapid and continued improvement in skin disease activity with separation from placebo observed as early as Week 4 (19.3% vs. 5.5%; Δ= 13.8; CI: 1.19, 26.46), as measured by Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity-50 (CLASI-50) response through Week 24 (40.8% vs. 21%; Δ= 19.8; CI: 1.46, 38.15). More participants receiving litifilimab achieved a response compared to placebo (21.7% vs 5.8%), as measured by CLASI-70 at Week 24. CLASI-50 and CLASI-70 responses are defined as 50 percent and 70 percent improvements from baseline in CLASI-A score, respectively. Additionally, 1 in 6 participants receiving litifilimab achieved a CLASI 0-3 score, defined as no or minimal disease activity, compared to placebo at Week 24 (16.3% vs 0%; Δ= 16.3; CI: 7.07, 25.62).

Litifilimab was generally well tolerated in Part A of the AMETHYST study and tolerability was consistent with the safety profile established in completed studies, including the Phase 2 LILAC study. Adverse events (AEs) were reported in 74.6% (44/59) and 64.7% (22/34) of participants receiving litifilimab and placebo, respectively, in the 24-week period. Most AEs were mild to moderate in severity. Serious adverse events occurred in 6.8% (4/59) and 2.9% (1/34) of participants receiving litifilimab and placebo, respectively.

“Cutaneous lupus erythematosus not only leaves scars but can also have a profound emotional and social impact on those living with the disease. With no approved targeted disease-modifying treatments, options for people living with CLE are very limited,” said Daniel Quirk, MD, Chief Medical Officer at Biogen. “We are excited to see results from two studies in which litifilimab was generally well tolerated and was associated with improvement in skin disease in a representative population, giving us encouraging momentum as we advance the Phase 3 program. The work Biogen has done in lupus and in CLE in particular demonstrates Biogen’s commitment to tackling diseases where options are limited or nonexistent.”

About AMETHYST
AMETHYST is a two-part, Phase 2/3 multicenter, double-blind, placebo controlled, randomized study to evaluate the efficacy and safety of litifilimab compared to placebo. The study aims to assess the efficacy of litifilimab in participants with active subacute cutaneous lupus erythematosus (SCLE) and/or chronic cutaneous lupus erythematosus (CCLE) who are refractory or intolerant to antimalarial therapy. The Phase 2 and Phase 3 parts of the study will each be 52 weeks in duration. Participants will be randomized to receive subcutaneous treatment with litifilimab or placebo every four weeks for 20 weeks with an additional dose at Week 2. All participants will receive litifilimab during the 28-week extended treatment period from Weeks 24 to 48. More information on the AMETHYST study (NCT05531565) is available at clinicaltrials.gov.

About Litifilimab (BIIB059)
Litifilimab (known as BIIB059), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting BDCA2 and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). BDCA2 is a receptor that is predominantly expressed on a subset of human immune cells called Plasmacytoid Dendritic Cells (pDCs). Binding of litifilimab to BDCA2 has been shown to reduce production of pro-inflammatory molecules by pDCs, including type-I interferon (IFN-I) as well as other cytokines and chemokines.1,2 These pro-inflammatory mediators are thought to play a major role in the pathogenesis of systemic and cutaneous lupus.

Litifilimab is an investigational therapeutic candidate that has not yet been approved by any regulatory authority and its safety and effectiveness have not been established.

About Cutaneous Lupus Erythematosus (CLE)
CLE, a type of lupus, is a serious chronic autoimmune skin disease that can occur with or without systemic manifestations; people with CLE frequently experience symptoms including rash, pain, itch and photosensitivity as well as skin damage that may worsen over time and can include irreversible scarring, alopecia and dyspigmentation that can be disfiguring and substantially impact quality of life.3-6 Currently, there are no approved targeted therapies for CLE and the last drug was approved in the 1950s.

About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor
This news release contains forward-looking statements, including: the potential clinical effects of litifilimab; the potential of litifilimab to improve the health, wellbeing and outcomes for patients with CLE; the potential benefits, safety and efficacy of litifilimab; potential regulatory discussions, submissions and approvals and the timing thereof; potential therapeutic options for the treatment of CLE; the potential of Biogen's commercial business and pipeline programs, including litifilimab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. 

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Digital Media Disclosure
From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

References:

Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129(3):1359-1371. doi:10.1172/JCI124466Pellerin A, Otero K, Czerkowicz JM, et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med. 2015;7(4):464-476. doi:10.15252/emmm.201404719Drenkard C, Barbour KE, Greenlund KJ, Lim SS. The Burden of Living With Cutaneous Lupus Erythematosus. Front Med (Lausanne). 2022 Aug 8;9:897987. doi: 10.3389/fmed.2022.897987. PMID: 36017007; PMCID: PMC9395260.Ogunsanya ME, Brown CM, Lin D, et al (2018). Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study. Int J Womens Dermatol. 4(3):152-158.Ogunsanya ME, Cho SK, Hudson A, Chong, BF (2019). Validation and reliability of a disease-specific quality of life measure in patients with cutaneous lupus erythematosus. Br J Dermatol. 180(6):1430-1437.Drenkard C, Parker S, Aspey LD, Gordon C, Helmick CG, Bao G, Lim SS. Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. Arthritis Care Res (Hoboken). 2019 Jan;71(1):95-103. doi: 10.1002/acr.23578. PMID: 29669194; PMCID: PMC6193862.

CompaniesMarch 28 (Reuters) - Incyte (INCY.O), opens new tab said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials.

The ​company tested the drug, povorcitinib, in patients with ‌moderate to severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps, abscesses and scarring, usually in areas where skin rubs ​together like the armpits or groin.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

The new data, ​presented at a medical meeting, showed that after 54 ⁠weeks of treatment, up to 71.4% of patients taking ​the drug achieved at least 50% reduction in abscesses and ​inflamed skin bumps in the trials.

The studies also showed that up to 57% of patients achieved major symptom reduction and up to 29% ​achieved complete clearance of key skin lesions.

Povorcitinib is a ​once-daily pill that works by blocking JAK1, a protein involved in the ‌inflammation ⁠that leads to painful abscesses and nodules.

Treatment options for the condition are limited and are mainly injectable drugs.

There are currently three FDA-approved treatments for the condition: AbbVie's (ABBV.N), opens new tab Humira, Novartis' (NOVN.S), opens new tab ​Cosentyx and ​UCB's (UCB.BR), opens new tab Bimzelx.

The most ⁠frequent side effects were acne, nasopharyngitis and upper respiratory tract infections, Incyte said.

Hidradenitis suppurativa ​affects about 1% to 4% of people in ​the ⁠United States and has a higher impact on people from racial and ethnic minority groups, according to the U.S. Food ⁠and ​Drug Administration.

Incyte said applications seeking approval ​of povorcitinib are currently under review by the FDA and the European Medicines ​Agency.

Reporting by Kamal Choudhury in Bengaluru. Editing by Alan Barona

Our Standards: The Thomson Reuters Trust Principles., opens new tab

, /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Trip.com Group Limited (NASDAQ: TCOM) publicly traded securities between April 30, 2024 and January 13, 2026, inclusive (the "Class Period"), have until Saturday, May 11, 2026 to seek appointment as lead plaintiff of the Trip.com class action lawsuit. Captioned De Wilde v. Trip.com Group Limited, No. 26-cv-01420 (E.D.N.Y.), the Trip.com class action lawsuit charges Trip.com and certain of Trip.com's top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Trip.com class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-trip-com-group-limited-class-action-lawsuit-tcom.html 

You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

CASE ALLEGATIONS: Trip.com, through its subsidiaries, operates as a travel service provider for accommodation reservation, transportation ticketing, packaged tours, in-destination, corporate travel management, and other travel-related services.

The Trip.com class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that defendants recklessly understated the regulatory risk facing Trip.com as a result of its monopolistic business activities.

The Trip.com class action lawsuit further alleges that on January 14, 2026, Bloomberg published an article titled "China Starts Antitrust Probe of Trip.com Ahead of Travel Peak," which stated that "China is investigating Trip.com . . . over alleged antitrust conduct, taking aim at the country's dominant online travel platform." The article further allegedly revealed that "[i]n September, the market regulator in Zhengzhou summoned Trip.com for violations of rules against setting 'unfair restrictions' on merchants' transactions and prices." On this news, the price of Trip.com American Depositary Shares fell approximately 19% over two trading sessions.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Trip.com publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Trip.com class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Trip.com investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Trip.com shareholder class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Trip.com class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 

Services may be performed by attorneys in any of our offices. 

Contact:

Robbins Geller Rudman & Dowd LLP

J.C. Sanchez

655 W. Broadway, Suite 1900, San Diego, CA 92101

800-449-4900

[email protected] 

SOURCE Robbins Geller Rudman & Dowd LLP

LOS ANGELES--(BUSINESS WIRE)---- $PODD--PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm.